Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 536

1.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ.

Blood. 2019 Feb 15. pii: blood-2018-10-877761. doi: 10.1182/blood-2018-10-877761. [Epub ahead of print]

PMID:
30770396
2.

Structured Crowdsourcing Enables Convolutional Segmentation of Histology Images.

Amgad M, Elfandy H, Khallaf HH, Atteya LA, Elsebaie MAT, Elnasr LSA, Sakr RA, Salem HSE, Ismail AF, Saad AM, Ahmed J, Elsebaie MAT, Rahman M, Ruhban IA, Elgazar NM, Alagha Y, Osman MH, Alhusseiny AM, Khalaf MM, Younes AF, Abdulkarim A, Younes DM, Gadallah AM, Elkashash AM, Fala SY, Zaki BM, Beezley J, Chittajallu DR, Manthey D, Gutman DA, Cooper LAD.

Bioinformatics. 2019 Feb 6. doi: 10.1093/bioinformatics/btz083. [Epub ahead of print]

PMID:
30726865
3.

Is hydroxypyridonate 3,4,3-LI(1,2-HOPO) a good competitor of fetuin for uranyl metabolism?

Younes A, Creff G, Beccia MR, Moisy P, Roques J, Aupiais J, Hennig C, Solari PL, Den Auwer C, Vidaud C.

Metallomics. 2019 Jan 15. doi: 10.1039/c8mt00272j. [Epub ahead of print]

PMID:
30644488
4.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
5.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Jan 7. doi: 10.1158/1078-0432.CCR-18-2435. [Epub ahead of print]

PMID:
30617130
6.

Appropriate use criteria adoption for PCI at an academic medical center.

Younes A, Hoff JS, Bojansky AM, Kalra A.

Eur Heart J. 2018 Dec 14;39(47):4136-4138. doi: 10.1093/eurheartj/ehy756. No abstract available.

PMID:
30551141
7.

Seroprevalence, isolation, molecular detection and genetic diversity of Toxoplasma gondii from small ruminants in Egypt.

Abd El-Razik KA, Barakat AMA, Hussein HA, Younes AM, Elfadaly HA, Eldebaky HA, Soliman YA.

J Parasit Dis. 2018 Dec;42(4):527-536. doi: 10.1007/s12639-018-1029-4. Epub 2018 Oct 15.

PMID:
30538350
8.

Novel therapeutic agents for relapsed classical Hodgkin lymphoma.

von Keudell G, Younes A.

Br J Haematol. 2019 Jan;184(1):105-112. doi: 10.1111/bjh.15695. Epub 2018 Dec 11. Review.

PMID:
30536386
9.

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM.

Br J Haematol. 2019 Mar;184(5):744-752. doi: 10.1111/bjh.15702. Epub 2018 Dec 5.

PMID:
30520026
10.

Endovascular Embolization of Post-tonsillectomy Pseudoaneurysm: A Single-Center Case Series.

Hassan F, Younes A, Rifai M.

Cardiovasc Intervent Radiol. 2018 Dec 5. doi: 10.1007/s00270-018-2131-9. [Epub ahead of print]

PMID:
30519726
11.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

12.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2018 Nov 15;3(22). pii: 125568. doi: 10.1172/jci.insight.125568. [Epub ahead of print] No abstract available.

13.

Excitation-Dependent Multiple Fluorescence of a Substituted 2-(2'-Hydroxyphenyl)benzoxazole.

Meisner QJ, Younes AH, Yuan Z, Sreenath K, Hurley JJM, Zhu L.

J Phys Chem A. 2018 Nov 29;122(47):9209-9223. doi: 10.1021/acs.jpca.8b07988. Epub 2018 Nov 15.

PMID:
30411891
14.

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.

Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12034-12039. doi: 10.1073/pnas.1806928115. Epub 2018 Nov 7.

15.

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.

Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M.

Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. Review.

PMID:
30296387
16.

Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.

Schoenhals JE, Cushman TR, Barsoumian HB, Li A, Cadena AP, Niknam S, Younes AI, Caetano MDS, Cortez MA, Welsh JW.

Front Immunol. 2018 Sep 20;9:2170. doi: 10.3389/fimmu.2018.02170. eCollection 2018.

17.

Surgery in perforated pediatric intestinal lymphoma.

Ahmed G, ElShafiey M, Abdelrahman H, Elsemary S, Elkinaai N, Romeih M, Mohy R, Younes A.

Eur J Surg Oncol. 2019 Feb;45(2):279-283. doi: 10.1016/j.ejso.2018.08.022. Epub 2018 Sep 6.

PMID:
30224248
18.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

19.

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A.

Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.

20.

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.

Matsuki E, Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2018 Aug 13. doi: 10.1097/PAI.0000000000000645. [Epub ahead of print]

PMID:
30106758
21.

Is Polonium-210 a Good Indicator for Anthropogenic Radioactivity?

Younes A, Alliot C, Mokili M, Montavon G.

Cancer Biother Radiopharm. 2018 Oct;33(8):356-360. doi: 10.1089/cbr.2018.2496. Epub 2018 Aug 8.

PMID:
30088970
22.

Phytochemical Screening and Antidiabetic, Antihyperlipidemic, and Antioxidant Properties of Anthyllis henoniana (Coss.) Flowers Extracts in an Alloxan-Induced Rats Model of Diabetes.

Ben Younes A, Ben Salem M, El Abed H, Jarraya R.

Evid Based Complement Alternat Med. 2018 Jun 24;2018:8516302. doi: 10.1155/2018/8516302. eCollection 2018.

23.

Genetic diversity and population structure of local and exotic sheep breeds in Jordan using microsatellites markers.

Jawasreh KI, Ababneh MM, Ismail ZB, Younes AMB, Sukhni IA.

Vet World. 2018 Jun;11(6):778-781. doi: 10.14202/vetworld.2018.778-781. Epub 2018 Jun 9.

24.

Surrogate end points in lymphoma.

Batlevi CL, Younes A.

Ann Oncol. 2018 Aug 1;29(8):1622-1623. doi: 10.1093/annonc/mdy219. No abstract available.

PMID:
29905757
25.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

26.

Visual Diagnosis: Syncopal Episode in a 14-year-old Adolescent Boy.

Younes A, Ekeruo IA, Evangelista MS.

Pediatr Rev. 2018 Jun;39(6):e27-e30. doi: 10.1542/pir.2016-0150. No abstract available.

PMID:
29858302
27.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 Nov 15;24(22):5735-5743. doi: 10.1158/1078-0432.CCR-17-3279. Epub 2018 May 21.

PMID:
29784675
28.

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.

Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW.

Cancer Lett. 2018 Sep 1;431:54-63. doi: 10.1016/j.canlet.2018.05.005. Epub 2018 May 8.

PMID:
29746927
29.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.

Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.

PMID:
29723393
30.

First experience of the Egyptian National Cancer Institute using the robot-assisted laparoscopic approach in radical hysterectomies for cervical cancer.

Zaghloul AS, El-Minawi AM, ElKordy MA, Younes AK, Mahmoud AM, Fadlalla WM, Mohamed GA.

J Egypt Natl Canc Inst. 2018 Jun;30(2):61-67. doi: 10.1016/j.jnci.2018.03.003.

31.

Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37.

Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa A, D Ovidio C, Younes A, Gallenga CE, Conti P.

J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2):195-198.

PMID:
29684996
32.

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM.

Blood Adv. 2018 Apr 24;2(8):871-876. doi: 10.1182/bloodadvances.2017011916.

33.

Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.

Chi G, Gibson CM, Hernandez AF, Hull RD, Kazmi SHA, Younes A, Walia SS, Pitliya A, Singh A, Kahe F, Kalayci A, Nafee T, Kerneis M, AlKhalfan F, Cohen AT, Harrington RA, Goldhaber SZ.

Am J Med. 2018 Aug;131(8):972.e1-972.e7. doi: 10.1016/j.amjmed.2018.03.031. Epub 2018 Apr 13.

PMID:
29660351
34.

Design, synthesis, biological evaluations, molecular docking, and in vivo studies of novel phthalimide analogs.

Zahran MAH, El-Aarag B, Mehany ABM, Belal A, Younes AS.

Arch Pharm (Weinheim). 2018 May;351(5):e1700363. doi: 10.1002/ardp.201700363. Epub 2018 Apr 3.

PMID:
29611624
35.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.

36.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas.

Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A.

Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-0432.CCR-17-3021. Epub 2018 Mar 13.

PMID:
29535129
37.

18F-fluoro-2-deoxyglucose positron emission-computed tomography in a rare cutaneous form of Rosai-Dorfman disease: A case report.

Hadchiti J, Kamar FG, Ghosn JA, Haidar M, Younes A, Obeid A, Haddad M, Farhat F, Chehade F.

Mol Clin Oncol. 2018 Feb;8(2):236-241. doi: 10.3892/mco.2017.1507. Epub 2017 Nov 21.

38.

Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW, Krishnan S.

Immunotherapy. 2018 Feb 1;10(4):299-316. doi: 10.2217/imt-2017-0082.

39.

Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Kerneis M, Talib U, Nafee T, Daaboul Y, Pahlavani S, Pitliya A, Furqan MM, Datta S, Kazmi HA, Younes A, Gibson CM.

Prog Cardiovasc Dis. 2018 Jan - Feb;60(4-5):524-530. doi: 10.1016/j.pcad.2018.01.008. Epub 2018 Feb 3. Review.

PMID:
29397950
40.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

PMID:
29394125
41.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH.

Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31.

PMID:
29386196
42.

Validation of the Modified Surgeon Periorbital Rating of Edema and Ecchymosis (SPREE) Questionnaire: A Prospective Analysis of Facial Plastic and Reconstructive Surgery Procedures.

Oliver JD, Menapace D, Younes A, Recker C, Hamilton G, Friedman O.

Facial Plast Surg. 2018 Feb;34(1):95-101. doi: 10.1055/s-0037-1615282. Epub 2018 Jan 11.

PMID:
29325183
43.

Revisiting the applicability of adult early post-operative nausea and vomiting risk factors for the paediatric patient: A prospective study using cotinine levels in children undergoing adenotonsillectomies.

Chau DF, Reddy A, Breheny P, Young AR, Ashford E, Song M, Zhang C, Taylor T, Younes A, Vazifedan T.

Indian J Anaesth. 2017 Dec;61(12):964-971. doi: 10.4103/ija.IJA_303_17.

44.

Authors' Reply.

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN.

J Mol Diagn. 2018 Jan;20(1):125-126. doi: 10.1016/j.jmoldx.2017.11.002.

45.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group.

N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: N Engl J Med. 2018 Mar 1;378(9):878.

46.

Recovery of steroid induced adrenal insufficiency.

Younes AK, Younes NK.

Transl Pediatr. 2017 Oct;6(4):269-273. doi: 10.21037/tp.2017.10.01. Review.

47.

Impact of sleep deprivation on anaesthesia residents' non-technical skills: a pilot simulation-based prospective randomized trial.

Neuschwander A, Job A, Younes A, Mignon A, Delgoulet C, Cabon P, Mantz J, Tesniere A.

Br J Anaesth. 2017 Jul 1;119(1):125-131. doi: 10.1093/bja/aex155.

48.

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, Turgut M, Gerecitano J, Kong O, Pisal CB, Tavorath R, Kim WS.

Haematologica. 2017 Dec;102(12):2104-2112. doi: 10.3324/haematol.2017.169656. Epub 2017 Sep 29.

49.

Revival of PI3K inhibitors in non-Hodgkin's lymphoma.

Batlevi CL, Younes A.

Ann Oncol. 2017 Sep 1;28(9):2047-2049. doi: 10.1093/annonc/mdx392. No abstract available.

PMID:
28911078
50.

Hearing Outcome With the Use of Glass Ionomer Cement as an Alternative to Crimping in Stapedotomy.

Elzayat S, Younes A, Fouad A, Erfan F, Mahrous A.

Otol Neurotol. 2017 Oct;38(9):1240-1245. doi: 10.1097/MAO.0000000000001564.

PMID:
28891873

Supplemental Content

Loading ...
Support Center